Bio-Techne (TECH) 53rd Annual Nasdaq Investor Conference summary

Business overview and strategic focus

• Offers 7,000 proteins and 400,000 antibodies, serving as foundational tools for life science research.

• Focuses on four high-growth application areas: cell therapy, proteomics, spatial biology, and molecular diagnostics.

• Core reagents are leveraged across all application areas, aligning with major industry trends.

Recent financial and operational highlights

• Cell therapy business experienced rapid but lumpy growth, with two major customers receiving FDA Fast Track approval, creating a temporary revenue gap.

• Large pharma segment achieved double-digit growth for three consecutive quarters; China returned to positive growth for two quarters.

• Protein analysis instruments and spatial biology businesses showed strong double-digit growth and bookings.

• Margins exceeded forecasts, reaching 29.9% due to operational efficiencies.

End-market trends and outlook

• Biopharma represents 50% of revenue, with large pharma showing resilience and biotech pressured by funding but showing recent improvement.

• Academic research accounts for 20% of revenue; U.S. segment faces uncertainty due to budget negotiations, while Europe remains stable.

• China, now 8% of revenue, is rebounding with increased activity in cell and gene therapies and is expected to grow at mid- to high-teens rates.